Trial Profile

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPY 001 (Primary) ; SPY 001 (Primary) ; SPY 002 (Primary) ; SPY 003 (Primary)
Indications Ulcerative colitis
Focus Proof of concept; Therapeutic Use
Acronyms SKYLINE-UC

05 Nov 2025 According to the Spyre Therapeutics Media Release, SKYLINE and SKYWAY trials are expected to provide 6 proof-of-concept readouts in 2026.
26 Jun 2025 The protocol has been amended to include an addition in the treatment arm, a change in allocation as randomized allocation, a change in the interventional study model as parallel assignment, and an addition in the safety endpoint.
26 Jun 2025 Planned number of patients changed from 35 to 645.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com